Citadel Advisors’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-990
| Closed | -$4.97K | – | 15796 |
|
|
2024
Q3 | $4.97K | Sell |
990
-230
| -19% | -$1.49K | ﹤0.01% | 13528 |
|
|
2024
Q2 | $8.05K | Buy |
+1,220
| New | +$8.3K | ﹤0.01% | 13214 |
|
|
2023
Q3 | – | Sell |
-1,704
| Closed | -$65.6K | – | 15641 |
|
|
2023
Q2 | $65.6K | Sell |
1,704
-246
| -13% | -$8.68K | ﹤0.01% | 11481 |
|
|
2023
Q1 | $54K | Buy |
1,950
+871
| +81% | +$29.5K | ﹤0.01% | 12055 |
|
|
2022
Q4 | $35.5K | Buy |
1,079
+244
| +29% | +$17.8K | ﹤0.01% | 12547 |
|
|
2022
Q3 | $101K | Sell |
835
-478
| -36% | -$86K | ﹤0.01% | 11092 |
|
|
2022
Q2 | $230K | Sell |
1,313
-251
| -16% | -$52.9K | ﹤0.01% | 10408 |
|
|
2022
Q1 | $454K | Sell |
1,564
-1,867
| -54% | -$708K | ﹤0.01% | 9627 |
|
|
2021
Q4 | $1.79M | Buy |
3,431
+2,100
| +158% | +$1.51M | ﹤0.01% | 6493 |
|
|
2021
Q3 | $506K | Buy |
1,331
+1,174
| +748% | +$503K | ﹤0.01% | 9832 |
|
|
2021
Q2 | $140K | Buy |
157
+87
| +124% | +$66.5K | ﹤0.01% | 12573 |
|
|
2021
Q1 | $83K | Buy |
+70
| New | +$96.5K | ﹤0.01% | 12620 |
|
Citadel Advisors's BIOR Position: Q2 2023 in Review
Citadel Advisors sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q2 2023, closing a stake of 139 shares — an estimated $4.9K sold.
Citadel Advisors first reported a position in BIOR in Q2 2020 and held it in 8 quarters. The position peaked at $900K in Q2 2020. 30 funds tracked by Wall St. Rank hold BIOR as of Q2 2023.
- Citadel Advisors reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Citadel Advisors sold 139 Biora Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $4.9K.
- Citadel Advisors first reported a position in Biora Therapeutics, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
- Citadel Advisors's Biora Therapeutics, Inc. Common Stock position peaked at $900K in Q2 2020.
- 30 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q2 2023.
Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.